- Home
- FIGS vs PHVS Comparison
FIGS vs PHVS Comparison
Compare FIGS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- PHVS
- Stock Information
- Founded
- FIGS 2013
- PHVS 2015
- Country
- FIGS United States
- PHVS Switzerland
- Employees
- FIGS N/A
- PHVS N/A
- Industry
- FIGS Apparel
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- PHVS Health Care
- Exchange
- FIGS Nasdaq
- PHVS Nasdaq
- Market Cap
- FIGS 1.1B
- PHVS 1.3B
- IPO Year
- FIGS 2021
- PHVS 2021
- Fundamental
- Price
- FIGS $6.89
- PHVS $23.05
- Analyst Decision
- FIGS Sell
- PHVS Buy
- Analyst Count
- FIGS 4
- PHVS 6
- Target Price
- FIGS $5.38
- PHVS $36.67
- AVG Volume (30 Days)
- FIGS 2.0M
- PHVS 124.7K
- Earning Date
- FIGS 11-06-2025
- PHVS 08-12-2025
- Dividend Yield
- FIGS N/A
- PHVS N/A
- EPS Growth
- FIGS N/A
- PHVS N/A
- EPS
- FIGS 0.04
- PHVS N/A
- Revenue
- FIGS $569,581,000.00
- PHVS N/A
- Revenue This Year
- FIGS $4.63
- PHVS N/A
- Revenue Next Year
- FIGS $3.69
- PHVS N/A
- P/E Ratio
- FIGS $158.69
- PHVS N/A
- Revenue Growth
- FIGS 3.41
- PHVS N/A
- 52 Week Low
- FIGS $3.57
- PHVS $11.51
- 52 Week High
- FIGS $7.31
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- FIGS 54.43
- PHVS 55.97
- Support Level
- FIGS $6.50
- PHVS $21.41
- Resistance Level
- FIGS $7.19
- PHVS $24.52
- Average True Range (ATR)
- FIGS 0.25
- PHVS 1.34
- MACD
- FIGS -0.06
- PHVS -0.15
- Stochastic Oscillator
- FIGS 48.47
- PHVS 47.24
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.